Skip to main content
TipRanks
Go Ultimate75% OFF

Immuneering (IMRX) Stock Statistics & Valuation Metrics

695 Followers

Total Valuation

Immuneering has a market cap or net worth of $240.27M. The enterprise value is $123.13M.

Market Cap
$240.27M
Enterprise Value
$123.13M

Share Statistics

Immuneering has 64,763,150 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
64,763,150
Owned by Insiders
9.37%
Owned by Institutions
43.87%

Financial Efficiency

Immuneering’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -26.71%.

Return on Equity (ROE)
-0.26
Return on Assets (ROA)
-0.24
Return on Invested Capital (ROIC)
-26.71%
Return on Capital Employed (ROCE)
-0.27
Revenue Per Employee
0
Profits Per Employee
-861.92K
Employee Count
65
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Immuneering is -3.46. Immuneering’s PEG ratio is -0.06.

PE Ratio
-3.46
PS Ratio
0.00
PB Ratio
1.37
Price to FCF
-3.74
Price to Operating Cash Flow
-3.75
PEG Ratio
-0.06

Income Statement

In the last 12 months, Immuneering had revenue of 0 and earned -56.02M in profits. Earnings per share was -1.27.

Revenue
0
Gross Profit
-698.89K
Operating Income
-59.38M
Pretax Income
-56.02M
Net Income
-56.02M
EBITDA
-55.67M
Earnings Per Share (EPS)
-1.27

Cash Flow

In the last 12 months, operating cash flow was -61.56M and capital expenditures -246,365, giving a free cash flow of -61.81M billion.

Operating Cash Flow
-61.56M
Free Cash Flow
-61.81M
Free Cash Flow per Share
-0.96

Dividends & Yields

Immuneering pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-27.11%
Earnings Yield
-29.19%

Stock Price Statistics

Beta
1.64
52-Week Price Change
-42.48%
50-Day Moving Average
4.00
200-Day Moving Average
4.75
Relative Strength Index (RSI)
47.40
Average Volume (3m)
709.75K

Important Dates

Immuneering upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).

Last Earnings Date
Oct 29, 2026
Next Earnings Date
Mar 11, 2027
Ex-Dividend Date
―

Financial Position

Immuneering as a current ratio of 17.50, with Debt / Equity ratio of 1.75%

Current Ratio
17.50
Quick Ratio
17.50
Debt to Market Cap
0.00
Net Debt to EBITDA
2.24
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Immuneering has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Immuneering EV to EBITDA ratio is -2.40, with an EV/FCF ratio of -2.80.

EV to Sales
0.00
EV to EBITDA
-2.40
EV to Free Cash Flow
-2.80
EV to Operating Cash Flow
-2.81

Balance Sheet

Immuneering has $145.41M in cash and marketable securities with $3.53M in debt, giving a net cash position of $141.87M billion.

Cash & Marketable Securities
$145.41M
Total Debt
$3.53M
Net Cash
$141.87M
Net Cash Per Share
$2.19
Tangible Book Value Per Share
$2.50

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Immuneering is $12.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
$12.50
Price Target Upside
236.93% Upside
Analyst Consensus
Moderate Buy
Analyst Count
2
Revenue Growth Forecast
―
EPS Growth Forecast
42.34%

Scores

Smart Score
8
AI Score
47